Vivienne Rebel - Aug 29, 2022 Form 3 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role
EVP, Chief Sci. & Med. Officer
Signature
/s/ Wilhelm E. Liebmann, as attorney-in-fact for Vivienne Rebel
Stock symbol
BIAF
Transactions as of
Aug 29, 2022
Transactions value $
$0
Form type
3
Date filed
11/22/2022, 03:47 PM
Next filing
Nov 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BIAF Common Stock, par value $0.007 7.14K Aug 29, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 2.86K $7.00 Direct F1, F2
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 2.86K $7.70 Direct F1, F3
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 4.29K $7.70 Direct F1, F4
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 4.29K $7.70 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities and exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering.
F2 Represents a right to purchase 2,857 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the Issuer's 2014 Equity Incentive Plan (the "EIP") on July 25, 2016. This option vested in 12 monthly installments beginning on August 25, 2016 and is fully vested and exercisable as of the date of this report.
F3 Represents a right to purchase 2,857 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the EIP on November 20, 2017. This option vested in 12 monthly installments beginning on December 20, 2017 and is fully vested and exercisable as of the date of this report.
F4 Represents a right to purchase 4,285 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the EIP on February 25, 2019. This option vested in 12 monthly installments beginning on March 25, 2019 and is fully vested and exercisable as of the date of this report.
F5 Represents a right to purchase 4,285 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the EIP on February 5, 2020. This option vested in 12 monthly installments beginning on March 5, 2020 and is fully vested and exercisable as of the date of this report.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney (Vivienne Rebel)